Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97845. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism, affecting almost 1 in 250 individuals worldwide. It is usually inherited via the autosomal dominant way and is characterized by aberrantly high total and low-density lipoprotein cholesterol (LDL-C) concentrations from early childhood, predisposing to increased risk of premature atherosclerotic cardiovascular disease (ASCVD), mostly coronary heart disease (CHD). Despite its high prevalence in the general population and the high ASCVD risk, FH is often un...
Source: Kardiologia Polska - November 8, 2023 Category: Cardiology Authors: Panagiotis Anagnostis Christina Antza Matilda Florentin Vasileios Kotsis Source Type: research
Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97845. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism, affecting almost 1 in 250 individuals worldwide. It is usually inherited via the autosomal dominant way and is characterized by aberrantly high total and low-density lipoprotein cholesterol (LDL-C) concentrations from early childhood, predisposing to increased risk of premature atherosclerotic cardiovascular disease (ASCVD), mostly coronary heart disease (CHD). Despite its high prevalence in the general population and the high ASCVD risk, FH is often un...
Source: Polish Heart Journal - November 8, 2023 Category: Cardiology Authors: Panagiotis Anagnostis Christina Antza Matilda Florentin Vasileios Kotsis Source Type: research
Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97845. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism, affecting almost 1 in 250 individuals worldwide. It is usually inherited via the autosomal dominant way and is characterized by aberrantly high total and low-density lipoprotein cholesterol (LDL-C) concentrations from early childhood, predisposing to increased risk of premature atherosclerotic cardiovascular disease (ASCVD), mostly coronary heart disease (CHD). Despite its high prevalence in the general population and the high ASCVD risk, FH is often un...
Source: Kardiologia Polska - November 8, 2023 Category: Cardiology Authors: Panagiotis Anagnostis Christina Antza Matilda Florentin Vasileios Kotsis Source Type: research
Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97845. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism, affecting almost 1 in 250 individuals worldwide. It is usually inherited via the autosomal dominant way and is characterized by aberrantly high total and low-density lipoprotein cholesterol (LDL-C) concentrations from early childhood, predisposing to increased risk of premature atherosclerotic cardiovascular disease (ASCVD), mostly coronary heart disease (CHD). Despite its high prevalence in the general population and the high ASCVD risk, FH is often un...
Source: Polish Heart Journal - November 8, 2023 Category: Cardiology Authors: Panagiotis Anagnostis Christina Antza Matilda Florentin Vasileios Kotsis Source Type: research
Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97845. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism, affecting almost 1 in 250 individuals worldwide. It is usually inherited via the autosomal dominant way and is characterized by aberrantly high total and low-density lipoprotein cholesterol (LDL-C) concentrations from early childhood, predisposing to increased risk of premature atherosclerotic cardiovascular disease (ASCVD), mostly coronary heart disease (CHD). Despite its high prevalence in the general population and the high ASCVD risk, FH is often un...
Source: Kardiologia Polska - November 8, 2023 Category: Cardiology Authors: Panagiotis Anagnostis Christina Antza Matilda Florentin Vasileios Kotsis Source Type: research
Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97845. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism, affecting almost 1 in 250 individuals worldwide. It is usually inherited via the autosomal dominant way and is characterized by aberrantly high total and low-density lipoprotein cholesterol (LDL-C) concentrations from early childhood, predisposing to increased risk of premature atherosclerotic cardiovascular disease (ASCVD), mostly coronary heart disease (CHD). Despite its high prevalence in the general population and the high ASCVD risk, FH is often un...
Source: Polish Heart Journal - November 8, 2023 Category: Cardiology Authors: Panagiotis Anagnostis Christina Antza Matilda Florentin Vasileios Kotsis Source Type: research
Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners
Kardiol Pol. 2023 Nov 8. doi: 10.33963/v.kp.97845. Online ahead of print.ABSTRACTFamilial hypercholesterolemia (FH) is the most common genetic disorder of lipid metabolism, affecting almost 1 in 250 individuals worldwide. It is usually inherited via the autosomal dominant way and is characterized by aberrantly high total and low-density lipoprotein cholesterol (LDL-C) concentrations from early childhood, predisposing to increased risk of premature atherosclerotic cardiovascular disease (ASCVD), mostly coronary heart disease (CHD). Despite its high prevalence in the general population and the high ASCVD risk, FH is often un...
Source: Kardiologia Polska - November 8, 2023 Category: Cardiology Authors: Panagiotis Anagnostis Christina Antza Matilda Florentin Vasileios Kotsis Source Type: research
Update on lipid lowering therapy in peripheral artery disease
Dtsch Med Wochenschr. 2023 Nov;148(22):1406-1411. doi: 10.1055/a-1956-9891. Epub 2023 Nov 2.ABSTRACTDespite clear guideline recommendations, only about every second PAD patient is prescribed statins, women less often than men. There is an international consensus that every PAD patient should be treated with statins, as these not only lower lipids but also stabilize plaque, resulting in a prognostic benefit. Limb-related endpoints (MALE) can be reduced by 24% compared to placebo by lowering lipids. The combination of low-dose, high-potency statin with ezetimibe can be equivalent to high-dose statin monotherapy and, with bet...
Source: Atherosclerosis - November 2, 2023 Category: Cardiology Authors: Katja Sibylle M ühlberg Source Type: research
The Impact of Dietary Cholesterol on Low-Density Lipoprotein: Lessons in Absorption and Overconsumption
JCEM Case Rep. 2023 Feb 24;1(2):luad013. doi: 10.1210/jcemcr/luad013. eCollection 2023 Mar.ABSTRACTThis case describes a 58-year-old woman with past medical history of ulcerative colitis, hyperlipidemia, and radiological evidence of atherosclerosis without prior cardiovascular disease who presented for management of hyperlipidemia. At baseline, her lipid panel in 2015 noted a calculated low-density lipoprotein (LDL-C) of 125 mg/dL (3.2 mmol/L). Over the course of the next 5 years, she developed severe LDL elevations to >400 mg/dL (>10.3 mmol/L) following the addition of 1600 mg dietary cholesterol daily achieved thro...
Source: Atherosclerosis - November 1, 2023 Category: Cardiology Authors: Michael Porter Melissa Wellons Source Type: research
Statin, Ezetimibe, or Fibrate Initiation and Subsequent Use for the Primary and Secondary Prevention of Cardiovascular Diseases among Japanese Patients Aged ≥55 Years: A Nationwide Cohort Study
Biol Pharm Bull. 2023;46(11):1548-1557. doi: 10.1248/bpb.b23-00336.ABSTRACTThe use of lipid-modifying agents (LMAs) other than statins has rarely been reported in real clinical settings. We aimed to compare the initiation and subsequent use of LMA classes for prevention of cardiovascular diseases. Using the national claims database, this retrospective cohort study was conducted on patients aged ≥55 years who initiated to use statins, ezetimibe, or fibrates between Fiscal Years (FYs) 2014 and 2017 as the first pharmacotherapy for dyslipidemia in Japan. A permissible gap for defining persistence was set as the median days ...
Source: Biological and Pharmaceutical Bulletin - November 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tomida Tsugumichi Sato Tomoji Yoshida Shoichi Senda Akira Nakatsuma Naomi Iihara Source Type: research
Statin, Ezetimibe, or Fibrate Initiation and Subsequent Use for the Primary and Secondary Prevention of Cardiovascular Diseases among Japanese Patients Aged ≥55 Years: A Nationwide Cohort Study
Biol Pharm Bull. 2023;46(11):1548-1557. doi: 10.1248/bpb.b23-00336.ABSTRACTThe use of lipid-modifying agents (LMAs) other than statins has rarely been reported in real clinical settings. We aimed to compare the initiation and subsequent use of LMA classes for prevention of cardiovascular diseases. Using the national claims database, this retrospective cohort study was conducted on patients aged ≥55 years who initiated to use statins, ezetimibe, or fibrates between Fiscal Years (FYs) 2014 and 2017 as the first pharmacotherapy for dyslipidemia in Japan. A permissible gap for defining persistence was set as the median days ...
Source: Biological and Pharmaceutical Bulletin - November 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tomida Tsugumichi Sato Tomoji Yoshida Shoichi Senda Akira Nakatsuma Naomi Iihara Source Type: research
Statin, Ezetimibe, or Fibrate Initiation and Subsequent Use for the Primary and Secondary Prevention of Cardiovascular Diseases among Japanese Patients Aged ≥55 Years: A Nationwide Cohort Study
Biol Pharm Bull. 2023;46(11):1548-1557. doi: 10.1248/bpb.b23-00336.ABSTRACTThe use of lipid-modifying agents (LMAs) other than statins has rarely been reported in real clinical settings. We aimed to compare the initiation and subsequent use of LMA classes for prevention of cardiovascular diseases. Using the national claims database, this retrospective cohort study was conducted on patients aged ≥55 years who initiated to use statins, ezetimibe, or fibrates between Fiscal Years (FYs) 2014 and 2017 as the first pharmacotherapy for dyslipidemia in Japan. A permissible gap for defining persistence was set as the median days ...
Source: Biological and Pharmaceutical Bulletin - November 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tomida Tsugumichi Sato Tomoji Yoshida Shoichi Senda Akira Nakatsuma Naomi Iihara Source Type: research
Statin, Ezetimibe, or Fibrate Initiation and Subsequent Use for the Primary and Secondary Prevention of Cardiovascular Diseases among Japanese Patients Aged ≥55 Years: A Nationwide Cohort Study
Biol Pharm Bull. 2023;46(11):1548-1557. doi: 10.1248/bpb.b23-00336.ABSTRACTThe use of lipid-modifying agents (LMAs) other than statins has rarely been reported in real clinical settings. We aimed to compare the initiation and subsequent use of LMA classes for prevention of cardiovascular diseases. Using the national claims database, this retrospective cohort study was conducted on patients aged ≥55 years who initiated to use statins, ezetimibe, or fibrates between Fiscal Years (FYs) 2014 and 2017 as the first pharmacotherapy for dyslipidemia in Japan. A permissible gap for defining persistence was set as the median days ...
Source: Biological and Pharmaceutical Bulletin - November 1, 2023 Category: Drugs & Pharmacology Authors: Junko Tomida Tsugumichi Sato Tomoji Yoshida Shoichi Senda Akira Nakatsuma Naomi Iihara Source Type: research
Association of lipid lowering drugs and the risk of systemic lupus erythematosus: a drug target Mendelian randomization
Conclusion: Evolocumab might provide a protective effect on the risk of SLE in the European population, but statins and ezetimibe might not have the protective effect. Further research is necessary to elucidate the specific mechanisms and potential therapeutic applications of PCSK9 inhibitors (evolocumab) in the context of SLE protection. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - October 30, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
ConclusionThe results suggest that SPC R10/E10 improve LDL-C reduction and goal achievement in Chinese patients with primary hypercholesterolemia not adequately controlled on statin therapy, without new safety findings.Trial RegistrationClinicalTrials.gov (NCT04669041). (Source: Advances in Therapy)
Source: Advances in Therapy - October 27, 2023 Category: Drugs & Pharmacology Source Type: research
